Search | Clinical Trials Finder

Conditions: Advanced Solid Tumor
Interventions: SGN1; Drug
Lead sponsor: Guangzhou Sinogen Pharmaceutical Co., Ltd; Other
Eligibility: 18 Years to 75 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 4
States / cities: Gilbert, Arizona • Orange, California • Detroit, Michigan + 1 more

Conditions: Hereditary Leiomyomatosis and Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma, Sporadic Papillary Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions: Atezolizumab, Bevacizumab, Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Computed Tomography with Contrast, Erlotinib, Magnetic Resonance Imaging, Positron Emission Tomography, Sodium Fluoride F-18; Biological · Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 13
States / cities: La Jolla, California • Atlanta, Georgia • Chicago, Illinois + 7 more

Conditions: Advanced Solid Tumor
Interventions: Lunresertib, RP-3500, Zedoresertib; Drug
Lead sponsor: Debiopharm International SA; Industry
Eligibility: 12 Years and older
Enrollment: 464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 17
States / cities: Los Angeles, California • San Francisco, California • New Haven, Connecticut + 12 more

Conditions: Arthroplasty, Replacement
Interventions: Control Arm: SMR Reverse Shoulder System, Investigational Arm: SMR Stemless Reverse; Device
Lead sponsor: Limacorporate S.p.a; Industry
Eligibility: 22 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 13
States / cities: Los Angeles, California • Denver, Colorado • Boca Raton, Florida + 9 more

Conditions: Lymphoma, Solid Tumors
Interventions: Chemotherapy, Eflapegrastim; Drug
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 1 Month to 17 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 5
States / cities: Valhalla, New York • Charlotte, North Carolina • Cleveland, Ohio + 1 more

Conditions: Ureteral Diseases
Interventions: Uriprene® Degradable Temporary Ureteral Stent; Device
Lead sponsor: Adva-Tec; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: Phoenix, Arizona • Los Angeles, California • Gainesville, Florida + 1 more

Conditions: Cholangiocarcinoma, Colorectal Cancer, Gastric Cancers, Pancreatic Cancer
Interventions: BOLD-100 in combination with FOLFOX Chemotherapy (Arms I-VI), BOLD-100 ± FOLFOX ± Bevacizumab Chemotherapy (Arm VII); Drug
Lead sponsor: Bold Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: Santa Monica, California • Tampa, Florida

Conditions: Fabry Disease
Interventions: migalastat; Drug
Lead sponsor: Amicus Therapeutics; Industry
Eligibility: Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Ann Arbor Stage I Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma, Plasmablastic Lymphoma
Interventions: Cyclophosphamide, Daratumumab, Doxorubicin, Doxorubicin Hydrochloride, Etoposide, Prednisone, Vincristine, Vincristine Sulfate; Drug · Biological
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 9
States / cities: Miami, Florida • Chicago, Illinois • Baltimore, Maryland + 6 more

Conditions: Acute Pain
Interventions: Arginine vasopressin, Observational learning, Saline, fMRI data aquisition; Drug · Behavioral · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cardiotoxicity, HER2/Neu Positive, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions: Carvedilol, Laboratory Biomarker Analysis, Patient Observation; Drug · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 491 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2031
U.S. locations: 577
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Hot Springs, Arkansas + 375 more

Conditions: Krabbe Disease
Interventions: Not listed
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: Not listed
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Dentofacial Deformities, Prognathism, Retrognathism
Interventions: Not listed
Lead sponsor: National Institute of Dental and Craniofacial Research (NIDCR); NIH
Eligibility: 2 Years to 100 Years
Enrollment: 2,400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2046
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: 1p36 Deletion Syndrome, 4p Deletion Syndrome, Non-Wolf-Hirschhorn Syndrome, 4p16.3 Microduplication Syndrome, Achalasia Cardia, Achalasia Icrocephaly Syndrome, Achalasia-Addisonian Syndrome, Acquired Ataxia, Acquired Myasthenia Gravis, Acrodysostosis, Activated PI3K Delta Syndrome (APDS), Addison Disease, Adult Hypophosphatasia, Adult Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia (ALSP), Adult-onset Autosomal Recessive Cerebellar Ataxia, Alagille Syndrome, Alcohol Related Ataxia, Alstrom Syndrome, Anal Fistula, Aniridia, Aniridia - Absent Patella, Aniridia - Cerebellar Ataxia - Intellectual Disability, Aniridia - Ptosis - Intellectual Disability - Familial Obesity, Aniridia - Renal Agenesis - Psychomotor Retardation, Aniridia-intellectual Disability Syndrome, Arginase 1 Deficiency, Ataxia - Genetic Diagnosis - Unknown, Ataxia - Oculomotor Apraxia Type 1, Ataxia - Other, Ataxia With Dementia, Ataxia With Vitamin E Deficiency, Ataxia-telangiectasia, Ataxia-telangiectasia Variant, Ataxia-telangiectasia-like Disorder, Atypical HUS, Atypical Hemolytic Uremic Syndrome, Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA), Autosomal Dominant Cerebellar Ataxia, Autosomal Dominant Cerebellar Ataxia Type 1, Autosomal Dominant Cerebellar Ataxia Type 2, Autosomal Dominant Cerebellar Ataxia Type 3, Autosomal Dominant Cerebellar Ataxia Type 4, Autosomal Dominant Cerebellar Ataxia, Deafness and Narcolepsy, Autosomal Dominant Optic Atrophy, Autosomal Dominant Spastic Ataxia, Autosomal Dominant Spastic Ataxia Type 1, Autosomal Dominant Spinocerebellar Ataxia Due to Repeat Expansions That do Not Encode Polyglutamine, Autosomal Dominant Spinocerebellar Ataxia Due to a Channelopathy, Autosomal Dominant Spinocerebellar Ataxia Due to a Point Mutation, Autosomal Dominant Spinocerebellar Ataxia Due to a Polyglutamine Anomaly, Autosomal Recessive Ataxia Due to PEX10 Deficiency, Autosomal Recessive Ataxia Due to Ubiquinone Deficiency, Autosomal Recessive Ataxia, Beauce Type, Autosomal Recessive Cerebellar Ataxia, Autosomal Recessive Cerebellar Ataxia - Blindness - Deafness, Autosomal Recessive Cerebellar Ataxia - Psychomotor Retardation, Autosomal Recessive Cerebellar Ataxia - Saccadic Intrusion, Autosomal Recessive Cerebellar Ataxia Due to STUB1 Deficiency, Autosomal Recessive Cerebellar Ataxia Due to a DNA Repair Defect, Autosomal Recessive Cerebellar Ataxia With Late-onset Spasticity, Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome, Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to KIAA0226 Deficiency, Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to TUD Deficiency, Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to WWOX Deficiency, Autosomal Recessive Cerebellar Ataxia-pyramidal Signs-nystagmus-oculomotor Apraxia Syndrome, Autosomal Recessive Congenital Cerebellar Ataxia, Autosomal Recessive Congenital Cerebellar Ataxia Due to GRID2 Deficiency, Autosomal Recessive Congenital Cerebellar Ataxia Due to MGLUR1 Deficiency, Autosomal Recessive Degenerative and Progressive Cerebellar Ataxia, Autosomal Recessive Metabolic Cerebellar Ataxia, Autosomal Recessive Spastic Ataxia, Autosomal Recessive Spastic Ataxia - Optic Atrophy - Dysarthria, Autosomal Recessive Spastic Ataxia With Leukoencephalopathy, Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay, Autosomal Recessive Stickler Syndrome, Autosomal Recessive Syndromic Cerebellar Ataxia, Axenfeld-Rieger Syndrome, Beckwith-Wiedemann Syndrome, Behcet's Disease, Benign Paroxysmal Tonic Upgaze of Childhood With Ataxia, Beta Mannosidosis, Beta-Mannosidosis, Biliary Atresia, Blau Syndrome, Bohring-Opitz Syndrome, Borjeson-Forssman-Lehman Syndrome, Brachydactyly - Nystagmus - Cerebellar Ataxia, Brain Abnormalities, Neurodegeneration, and Dysosteosclerosis, Brain Tumor Ataxia, Breast Implant-Associated Anaplastic Large Cell Lymphoma, CRB1, CRELD1 (Cysteine Rich With EGF Like Domains 1), CRMO, CSF1R Related Disease (CSF1R-RD), Cataract - Ataxia - Deafness, Cauda Equina Syndrome, Caudal Regression, Cerebellar Ataxia - Areflexia - Pes Cavus - Optic Atrophy - Sensorineural Hearing Loss, Cerebellar Ataxia - Ectodermal Dysplasia, Cerebellar Ataxia - Hypogonadism, Cerebellar Ataxia With Peripheral Neuropathy, Cerebellar Ataxia, Cayman Type, Childhood-onset Autosomal Recessive Slowly Progressive Spinocerebellar Ataxia, Childhood-onset Hypophosphatasia, Chronic Recurrent Multifocal Osteomyelitis, Cockayne Syndrome, Coffin Lowry Syndrome, Congenital Sucrase-Isomaltase Deficiency, Constitutional Mismatch Repair Deficiency (CMMRD), Cornelia De Lange Syndrome, Cystinosis, DHDDS Gene Mutations, DNM1, Denys-Drash Syndrome, Dilated Cardiomyopathy With Ataxia, Disorders of Unknown Prevalence, EIEE31, Early-onset Ataxia With Dementia, Early-onset Cerebellar Ataxia With Retained Tendon Reflexes, Early-onset Progressive Neurodegeneration - Blindness - Ataxia - Spasticity, Early-onset Spastic Ataxia-neuropathy Syndrome, Emanuel Syndrome, Eosinophilic Gastroenteritis, Epilepsy and/or Ataxia With Myoclonus as Major Feature, Episodic Ataxia Type 1, Episodic Ataxia Type 3, Episodic Ataxia Type 4, Episodic Ataxia Type 5, Episodic Ataxia Type 6, Episodic Ataxia Type 7, Episodic Ataxia Unknown Type, Episodic Ataxia With Slurred Speech, Exposure to Medications Ataxia, Familial Paroxysmal Ataxia, Fish Odor Syndrome, Fragile X-associated Tremor/Ataxia Syndrome, Frasier Syndrome, Friedreich Ataxia, GAD Ataxia, GNB1 Gene Mutation, GNB1 Syndrome, Gliadin/Gluten Ataxia, Glycogen Storage Disease, HSPB8 Myopathy, Halitosis, Hemophagocytic Lymphohistiocytosis, Hereditary Diffuse Leukoencephalopathy With Axonal Spheroids and Pigmented Glia, Hereditary Episodic Ataxia, Hereditary Myopathy With Early Respiratory Failure, Hereditary Sensory and Autonomic Neuropathy Type Ie, Hirschsprung Disease, Hyperacusis (Hyperacousis), Hypersomnolence Disorder, Hypertrophic Olivary Degeneration, Hypnic Jerking, Hypophosphatasia, Idiopathic Gastroparesis, Idiopathic Hypersomnia, Idiopathic Hypersomnia With Long Sleep Time, Idiopathic Hypersomnia Without Long Sleep Time, Inclusion Body Myopathy With Early-onset Paget Disease and Frontotemporal Dementia (IBMPFD), Infantile Hypophosphatasia, Infection or Post Infection Ataxia, Intestinal Pseudo-Obstruction, Isolated Aniridia, Isolated Congenital Asplenia, Isolated Klippel-Feil Syndrome, Jansen Type Metaphyseal Chondrodysplasia, Juvenile Myasthenia Gravis, Juvenile Nephropathic Cystinosis, KCNMA1-Channelopathy, Kabuki Syndrome, Kawasaki Disease, Kbg Syndrome, Kennedy Disease, Kleine-Levin Syndrome, Labrune Syndrome, Lambert Eaton (LEMS), Laryngeal Papillomatosis, Late-onset Ataxia With Dementia, Leber Congenital Amaurosis, Leigh Syndrome, Leiomyosarcoma, Leiomyosarcoma of Small Intestine, Leiomyosarcoma of the Cervix Uteri, Leiomyosarcoma of the Corpus Uteri, Lesch-Nyhan Disease, Leukodystrophy, Lowe Syndrome, Lyme Disease, MAND-MBD5-Associated Neurodevelopmental Disorder, Machado-Joseph Disease Type 1, Machado-Joseph Disease Type 2, Machado-Joseph Disease Type 3, Malan Syndrome, Marinesco Sjogren Syndrome(Marinesco-Sjogren Syndrome), Maternally-inherited Leigh Syndrome, Metachromatic Leukodystrophy (MLD), Mitochondrial Aminoacyl-tRNA Synthetases, Mitochondrial Diseases, Mollaret Meningitis, Moyamoya Disease, Mt-aaRS Disorders, Mucolipidoses, Mucolipidosis Type 4, Multi-systematic Smooth Muscle Dysfunction Syndrome, Multiple Endocrine Neoplasia, Multiple Endocrine Neoplasia (MEN) Syndrome, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2, Multiple Endocrine Neoplasia Type 2A, Multiple Endocrine Neoplasia Type 2B, Multiple Endocrine Neoplasia Type II, Multiple Endocrine Neoplasia, Type 3, Multiple Endocrine Neoplasia, Type IV, Multiple System Atrophy, Multiple System Atrophy, Cerebellar Type, Multiple System Atrophy, Parkinsonian Type, Muscular Atrophy - Ataxia - Retinitis Pigmentosa - Diabetes Mellitus, Myasthenia Gravis, Myhre Syndrome, Myoclonus - Cerebellar Ataxia - Deafness, NARP Syndrome, Narcolepsy Without Cataplexy, Narcolepsy-cataplexy, Nasu-Hakola Disease, Nephropathic Cystinosis, Nicolaides Baraitser Syndrome, Non Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature, Non-Ketotic Hyperglycinemia, Non-hereditary Degenerative Ataxia, OPHN1 Syndrome, Oculopharyngeal Muscular Dystrophy (OPMD), Odontohypophosphatasia, Olivopontocerebellar Atrophy - Deafness, Paroxysmal Dystonic Choreathetosis With Episodic Ataxia and Spasticity, Parry Romberg Syndrome, Perinatal Lethal Hypophosphatasia, Peters Anomaly, Peters Anomaly - Cataract, Pierpont Syndrome, Pitt Hopkins Syndrome, Polyneuropathy - Hearing Loss - Ataxia - Retinitis Pigmentosa - Cataract, Post Vaccination Ataxia, Post-Head Injury Ataxia, Post-Stroke Ataxia, Posterior Column Ataxia - Retinitis Pigmentosa, Potocki-Shaffer Syndrome, Prenatal Benign Hypophosphatasia, Primary Biliary Cirrhosis, Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature, Pyruvate Dehydrogenase Complex Deficiency Disease, Rare Ataxia, Rare Disorders, Rare Gastrointestinal Disorders, Rare Hereditary Ataxia, Rare Inflammatory Bowel Disease, Rare Retinal Disorder, Recessive Mitochondrial Ataxia Syndrome, Recurrent Respiratory Papillomatosis, Recurrent Viral Meningitis, Refsum Disease, Retinitis Pigmentosa, SCAR12, SMC1A Truncated Mutations (Causing Loss of Gene Function), SPATA5 Disorder, SPATA5L1 Related Disorder, STAG1 Gene Mutation, Sacral Agenesis, Sacral Agenesis Syndrome, Scheuermann Disease, Scleroderma, Short Bowel Syndrome, Silver-Russell Syndrome Due to 11p15 Microduplication, Silver-Russell Syndrome Due to Imprinting Defect of 11p15, Silver-Russell Syndrome Due to Maternal Uniparental Disomy of Chromosome 11, Skraban-Deardorff Syndrome, Sleep Myoclonus, Spastic Ataxia, Spastic Ataxia - Corneal Dystrophy, Spastic Ataxia With Congenital Miosis, Spasticity-ataxia-gait Anomalies Syndrome, Spinal Bulbar Muscular Atrophy, Spinocerebellar Ataxia - Dysmorphism, Spinocerebellar Ataxia - Unknown, Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 1 With Axonal Neuropathy, Spinocerebellar Ataxia Type 10, Spinocerebellar Ataxia Type 11, Spinocerebellar Ataxia Type 12, Spinocerebellar Ataxia Type 13, Spinocerebellar Ataxia Type 14, Spinocerebellar Ataxia Type 15/16, Spinocerebellar Ataxia Type 16, Spinocerebellar Ataxia Type 17, Spinocerebellar Ataxia Type 18, Spinocerebellar Ataxia Type 19/22, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 20, Spinocerebellar Ataxia Type 21, Spinocerebellar Ataxia Type 22, Spinocerebellar Ataxia Type 23, Spinocerebellar Ataxia Type 25, Spinocerebellar Ataxia Type 26, Spinocerebellar Ataxia Type 27, Spinocerebellar Ataxia Type 28, Spinocerebellar Ataxia Type 29, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia Type 30, Spinocerebellar Ataxia Type 31, Spinocerebellar Ataxia Type 32, Spinocerebellar Ataxia Type 34, Spinocerebellar Ataxia Type 35, Spinocerebellar Ataxia Type 36, Spinocerebellar Ataxia Type 37, Spinocerebellar Ataxia Type 4, Spinocerebellar Ataxia Type 5, Spinocerebellar Ataxia Type 6, Spinocerebellar Ataxia Type 7, Spinocerebellar Ataxia Type 8, Spinocerebellar Ataxia With Axonal Neuropathy Type 2, Spinocerebellar Ataxia With Epilepsy, Spinocerebellar Ataxia With Oculomotor Anomaly, Sporadic Adult-onset Ataxia of Unknown Etiology, Stickler Syndrome, Stickler Syndrome Type 1, Stickler Syndrome Type 2, Syndromic Aniridia, TBL1XR1 Gene Variant, TBX4 Syndrome, TUBB3 Mutation, Tango2, Thyroid Antibody Ataxia, Toxic Exposure Ataxia, Tracheal Papillomatosis, Transient Global Amnesia, Transient Neonatal Myasthenia Gravis, Unclassified Autosomal Dominant Spinocerebellar Ataxia, Undiagnosed Disorders, VCP Disease, Vitamin B12 Deficiency Ataxia, WAGR Syndrome, WOREE (WWOX-related Epileptic Encephalopathy, Warburg Micro Syndrome, White Sutton Syndrome, Wiedemann-Steiner Syndrome, Williams Syndrome, Wolf-Hirschhorn Syndrome, X-linked Cerebellar Ataxia, X-linked Intellectual Disability - Ataxia - Apraxia, X-linked Non Progressive Cerebellar Ataxia, X-linked Progressive Cerebellar Ataxia, X-linked Spinocerebellar Ataxia Type 3, X-linked Spinocerebellar Ataxia Type 4, ZMYND11
Interventions: Not listed
Lead sponsor: Sanford Health; Other
Eligibility: Not listed
Enrollment: 20,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2100
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Electron Transport Chain Disorders, Mitochondrial, Leigh Disease, Mitochondrial Disorders, Oxidative Phosphorylation Deficiencies
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 4 Weeks to 115 Years
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nonmalignant Neoplasm
Interventions: biologic sample preservation procedure, cytology specimen collection procedure; Other
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 15,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2040
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Glycogen Storage Disease Type II, Pompe Disease
Interventions: Not listed
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: Not listed
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2034
U.S. locations: 98
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 72 more

Conditions: Healthy Adult Females, Healthy Adult Males
Interventions: Refined White Rice, Whole-Grain Brown Rice; Dietary Supplement
Lead sponsor: North Carolina Agriculture & Technical State University; Other
Eligibility: 25 Years to 70 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027
U.S. locations: 1
States / cities: Kannapolis, North Carolina

Conditions: HNSCC, Neoplasm Recurrence, Local, Recurrent Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Squamous Cell Carcinoma of Head and Neck (SCCHN)
Interventions: TMV Vaccine, Toripalimab-tpzi; Biological
Lead sponsor: Metaclipse Therapeutics Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Male Hypogonadism
Interventions: Testosterone Cypionate 75 mg, Testosterone cypionate 100 mg, Testosterone cypionate 50 mg; Drug
Lead sponsor: Amneal Pharmaceuticals, LLC; Industry
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 10
States / cities: Santa Monica, California • DeLand, Florida • Miami Lakes, Florida + 7 more

Conditions: Deterioration, Clinical
Interventions: Orientation day with rapid response nurse; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Cardiac Arrest, Out-Of-Hospital, Hypotension
Interventions: Not listed
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years and older
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 8
States / cities: Denver, Colorado • Worcester, Massachusetts • Lebanon, New Hampshire + 5 more

Conditions: Air Trapping, Emphysema, Hyperinflation
Interventions: Apreo BREATHE Airway Scaffold, Hyperpolarized Xenon MRI; Device · Drug
Lead sponsor: Apreo Health, Inc.; Industry
Eligibility: 40 Years to 84 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Birmingham, Alabama • Kansas City, Kansas

Conditions: Depression - Major Depressive Disorder
Interventions: Approach-Avoidance Decision-Making Task; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

Study of SGN1 in Patients With Advanced Solid Tumor

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

Study of Lunresertib Alone or in Combination With RP-3500 or Zedoresertib (Debio 0123) in Patients With Advanced Solid Tumors

SMR Stemless Reverse vs SMR Reverse Shoulder System

A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy

Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy

BOLD-100 in Combination With FOLFOX With or Without Bevacizumab for the Treatment of Advanced, Solid Tumours

A Global Prospective Observational Study of Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding

A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

Vasopressin and Pain Perception in the Brain

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

Krabbe Disease Global Patient Registry

Natural History of Craniofacial Anomalies and Developmental Growth Variants

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

The NIH MINI Study: Metabolism, Infection, and Immunity in Inborn Errors of Metabolism

Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

Pompe Disease Registry Protocol

Pharmacokinetic (PK) Study of Phytochemicals in Whole Grains (WGs)- Brown Rice

TMV Vaccine Alone or With Toripalimab-tpzi for Recurrent Head and Neck Squamous Cell Carcinoma

Safety and Efficacy of Weekly Testosterone Cypionate Auto-Injector in Men With Hypogonadism

The Orientation Intervention to Rapid Response Teams (ORIENT-RRT) Study: A Quasi-Experimental Study

Cardiac Arrest - Ultrasound Detection of Occult Perfusion

Xenon MRI to Evaluate Changes to Lung Function Following Bronchoscopic Treatment of Air Trapping in Emphysema

Understanding the Neural Underpinnings of Risk-Taking Behavior in Psychiatric Disease